In my view, there is sufficient evidence that external beam radiation therapy (EBRT) in the doses used to treat adenocar-cinoma of the prostate leads to a small but definite risk of in-field, and likely other, malignancies. There are at least 2 implications after the clinician acknowledges this. The first relates to the discussion with men with newly diagnosed clinically localized prostate cancer (PC).
展开▼
